The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.
•The duration of this study is 3 months. This includes:
* Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.
* Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.
* Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.

Start Date25 May 2026

Sponsor / Collaborator

University of Pittsburgh

[+1]

NCT07537088

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).

Start Date01 May 2026

Sponsor / Collaborator

Wannan Medical College

ChiCTR2600123454

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

Start Date01 May 2026

Sponsor / Collaborator

Wannan Medical College

100 Clinical Results associated with Dulaglutide

100 Translational Medicine associated with Dulaglutide

100 Patents (Medical) associated with Dulaglutide

1,660

Literatures (Medical) associated with Dulaglutide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Calculating cost per event avoided using a composite number needed to treat

Article

Author: Wang, Julia ; Bhavsar, Jigish ; Toliver, Joshua ; Sullivan, Sean D.

OBJECTIVE:

Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints. This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.

METHODS:

Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg). NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate. NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM). CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.

RESULTS:

The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT_MACE-3, NNT_MACE-5, and NNT_CKM were 67, 49, and 8 for semaglutide, and 72, 64, and 23 for dulaglutide, respectively. Similarly, the CPEA decreased as the number of outcomes in the composite endpoint increased, where the CPEA for MACE-3, MACE-5 and CKM calculations were $1,662,001, $1,232,417, and $190,387 for semaglutide and $1,884,013, $1,670,366, and $607,886 for dulaglutide.

CONCLUSIONS:

This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment. When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.

31 Dec 2026·ANNALS OF MEDICINE

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers

Review

Author: Chikatimalla, Rahul ; Aggarwal, Kanishk ; Perry, Griffin ; Shah, Twinkle ; Shah, Ashka ; Banker, Himanshi ; Jain, Rohit

OBJECTIVES:

To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention.

METHODS:

A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy.

RESULTS:

GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities.

CONCLUSION:

GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.

01 Sep 2026·MOLECULAR PSYCHIATRY

GLP-1 receptor agonists and risk of suicide or suicide attempts – A nationwide cohort and self-controlled case series study

Article

Author: Vinberg, Maj ; Winther-Jensen, Matilde ; Stanislaus, Christoffer ; Osler, Merete ; Coello, Klara ; Stanislaus, Sharleny

Abstract:

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have raised concerns about a potential link between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicide or suicide attempts. We conducted two new-user, active comparator cohort studies. The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs ( n = 83,464 ) or SGLT-2 inhibitors ( n = 78,366 ), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs ( n = 108,322 ) or DPP-4 inhibitors ( n = 55,411 ). We also employed a self-controlled case series design to compare suicide, or suicide attempts before and after GLP-1 RA treatment initiation across three time periods. In the cohort analyses patients who initiated GLP-1 RAs did not differ in the hazard ratio (HR) for suicide or suicide attempts from SGLT-2 inhibitor users (HR: 0.93; 95% CI: 0.57–1.52), and GLP-1 RA users had a lower risk of suicide or suicide attempts compared with DPP-4 inhibitor users (HR: 0.58; 95% CI: 0.37–0.91). In the self-controlled case series design, use of GLP-1 RAs was associated with a lower incidence rate ratio (IRR) of suicide or suicide attempts one year after treatment initiation (IRR: 0.45; 95% CI: 0.10–0.50) and 13–24 months after treatment initiation compared with pretreatment. This study showed that use of GLP-1 RAs was not associated with increased incidence of suicide or suicide attempts in either the active comparator new-user design or in the self-controlled case series design.

556

News (Medical) associated with Dulaglutide

11 Sep 2026

·allsci.com

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I

China-based Gan & Lee Pharmaceuticals Co., Ltd. has dosed the first participant in a Phase I study of GZC8072, an oral peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) engineered for once-weekly administration. The candidate targets type 2 diabetes mellitus (T2DM) and weight management in people with obesity or overweight, and its entry into clinical testing adds to a field of oral GLP-1 agents. The study CTR20263271 is a multicenter, randomized, double-blind, placebo-controlled Phase I trial enrolling 112 participants. A single ascending dose (SAD) portion will evaluate safety and tolerability in healthy adults; a multiple ascending dose (MAD) portion will enroll participants with overweight or obesity. Primary endpoints cover safety and tolerability; pharmacokinetic and pharmacodynamic data will also be collected. GZC8072 is built on two proprietary platforms Gan & Lee calls NovaPeptide, intended to extend peptide half-life and support manufacturing, and SupOraTide, designed to improve oral bioavailability. The company said the combination yields enhanced intrinsic GLP-1 receptor activity, a prolonged pharmacokinetic half-life, and sufficient oral absorption to support weekly dosing. GZC8072 sits alongside bofanglutide (GZR18), a biweekly injectable GLP-1 RA currently in Phase III trials in China and Phase II in the US, and Insulin Ludefen (GZR4), an ultra-long-acting weekly basal insulin analog. GLP-1 is an incretin hormone secreted from intestinal L-cells that stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts centrally to reduce appetite. Its plasma half-life of roughly one to two minutes, owing to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), makes native GLP-1 clinically unusable without structural modification. Approved peptide GLP-1 RAs extend half-life through fatty acid conjugation enabling albumin binding — the basis for semaglutide's approximately 160-hour half-life — or through other stabilisation strategies. GZC8072 applies a distinct proprietary approach to achieve weekly oral dosing, though preclinical pharmacokinetic data have not been publicly disclosed. Oral semaglutide (Rybelsus), approved for T2DM, relies on the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate (SNAC) and requires fasting administration with limited water. The US FDA approved oral semaglutide tablets under the Wegovy brand for obesity management on December 22, 2025. Eli Lilly and Company's orforglipron (Foundayo), a non-peptide small-molecule GLP-1 RA, received FDA approval in April 2025. Notably, Innovent Biologics’ IBI3042, an oral non-peptide small-molecule GLP-1 receptor agonist also designed for once-weekly dosing that entered Phase I development in September 2026. IBI3042 also entered first-in-human testing earlier this month. GZC8072 therefore enters an emerging race to establish whether weekly oral GLP-1 dosing can be achieved, although its peptide-based approach distinguishes it from Innovent’s small-molecule strategy. Weekly oral dosing could differentiate GZC8072 from currently approved daily oral GLP-1 therapies, while retaining a peptide-based pharmacology distinct from small-molecule agonists such as orforglipron. Real-world adherence to injectable GLP-1 RAs at six months has been reported at 58–69%, supporting the rationale for more convenient oral formulations. Whether GZC8072's proprietary delivery platforms achieve bioavailability sufficient to produce clinically meaningful receptor engagement will be the central question Phase I pharmacokinetic data must answer. Spot something wrong? Report an issue with this article

Phase 1Drug ApprovalPhase 2PDCPhase 3

10 Sep 2026

·www.businesswire.com

BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

PARIS--(BUSINESS WIRE)--BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. "GLP-1 medicines have changed how obesity and metabolic disease are treated, but we still need better oral options," said Dr. Farid Bennis, Founder of BioLife and inventor of the technology known internally as OralMatrix. The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market.1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow. First generation oral GLP-1 medicines have demonstrated the value of oral administration while also underscoring on the fundamental challenges in peptide drug development: protecting large peptide molecules as they move through the gastrointestinal tract. BioLife’s unique technology was developed to explore what comes next. Built on more than 35 years of pharmaceutical effervescence expertise, this novel approach to oral peptide delivery uses a dissolvable effervescent tablet format that creates a first-of-its-kind gastric buffer designed to help protect peptide therapeutics through the digestive system and support their absorption. "GLP-1 medicines have changed how obesity and metabolic disease are treated, but we still need better oral options," said Dr. Farid Bennis, Founder of BioLife and inventor of the technology known internally as OralMatrix. "This patent represents much more than protection for a formulation. It reflects decades of scientific work focused on addressing on the most important challenges in peptide medicine: helping these molecules pass through the digestive system intact, for today’s therapies and for future generations of peptide therapeutics." The technology takes a different approach to oral peptide drug delivery. Rather than relying on special coatings or absorption-enhancing ingredients, it uses a dissolvable effervescent format designed to help protect peptide medicines as they move through the digestive system. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept for the approach. The granted U.S. claims extend across the GLP-1 class, including semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. Patent protection runs into 2042 with additional patent applications pending internationally. Oral peptide drug delivery remains an important area of innovation as pharmaceutical companies evaluate increasingly sophisticated therapies for obesity, diabetes and metabolic disease. The opportunity extends beyond today's GLP-1 medicines and toward future generations of peptide therapeutics. About the Technology BioLife’s patented effervescent peptide delivery technology uses a dissolvable tablet format designed to support oral delivery of peptide medicines, including GLP-1 therapies. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration. The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and collaborations with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology is in development and is not approved for the treatment of any disease. About Dr. Farid Bennis Dr. Farid Bennis, eminent expert in effervescence research and technology is the founder of BioLife, named inventor on U.S. Patent No. 12,667,605 B2, and Chairman of the pharmaceutical company Laprophan Group, established in 1949 and present in more than 40 countries. Over more than 35 years, Dr Bennis has developed pharmaceutical effervescence technologies across multiple therapeutic areas, resulting in numerous patented inventions and commercialized healthcare products. The technology reflects nearly two decades of work devoted to oral peptide delivery. About BioLife BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research. The company's technology portfolio and related patent estate have been independently developed and are wholly owned. Sources 1 Managed Healthcare Executive, "GLP-1 Drugs to Drive Growth in Obesity and Diabetes Treatment," reporting IQVIA market data presented at AMCP Annual 2026. Available at: https://www.managedhealthcareexecutive.com/view/glp-1-drugs-to-drive-growth-in-obesity-and-diabetes-treatment-amcp-annual-2026

10 Sep 2026

·www.biospace.com

BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

Preclinical studies demonstrate measurable systemic semaglutide exposure following oral administration; granted claims cover semaglutide and multiple GLP-1 receptor agonists. PARIS--(BUSINESS WIRE)-- BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market. 1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow. First generation oral GLP-1 medicines have demonstrated the value of oral administration while also underscoring on the fundamental challenges in peptide drug development: protecting large peptide molecules as they move through the gastrointestinal tract. BioLife’s unique technology was developed to explore what comes next. Built on more than 35 years of pharmaceutical effervescence expertise, this novel approach to oral peptide delivery uses a dissolvable effervescent tablet format that creates a first-of-its-kind gastric buffer designed to help protect peptide therapeutics through the digestive system and support their absorption. "GLP-1 medicines have changed how obesity and metabolic disease are treated, but we still need better oral options," said Dr. Farid Bennis, Founder of BioLife and inventor of the technology known internally as OralMatrix. "This patent represents much more than protection for a formulation. It reflects decades of scientific work focused on addressing on the most important challenges in peptide medicine: helping these molecules pass through the digestive system intact, for today’s therapies and for future generations of peptide therapeutics." The technology takes a different approach to oral peptide drug delivery. Rather than relying on special coatings or absorption-enhancing ingredients, it uses a dissolvable effervescent format designed to help protect peptide medicines as they move through the digestive system. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept for the approach. The granted U.S. claims extend across the GLP-1 class, including semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. Patent protection runs into 2042 with additional patent applications pending internationally. Oral peptide drug delivery remains an important area of innovation as pharmaceutical companies evaluate increasingly sophisticated therapies for obesity, diabetes and metabolic disease. The opportunity extends beyond today's GLP-1 medicines and toward future generations of peptide therapeutics. About the Technology BioLife’s patented effervescent peptide delivery technology uses a dissolvable tablet format designed to support oral delivery of peptide medicines, including GLP-1 therapies. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration. The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and collaborations with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology is in development and is not approved for the treatment of any disease. About Dr. Farid Bennis Dr. Farid Bennis, eminent expert in effervescence research and technology is the founder of BioLife, named inventor on U.S. Patent No. 12,667,605 B2, and Chairman of the pharmaceutical company Laprophan Group, established in 1949 and present in more than 40 countries. Over more than 35 years, Dr Bennis has developed pharmaceutical effervescence technologies across multiple therapeutic areas, resulting in numerous patented inventions and commercialized healthcare products. The technology reflects nearly two decades of work devoted to oral peptide delivery. About BioLife BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research. The company's technology portfolio and related patent estate have been independently developed and are wholly owned. Sources 1 Managed Healthcare Executive, "GLP-1 Drugs to Drive Growth in Obesity and Diabetes Treatment," reporting IQVIA market data presented at AMCP Annual 2026. Available at: Contacts Media & Partner Enquiries US: Peter Opitz 608-712-9614 Europe: Misha Talheth-Fells +447548907984 Business & Licensing: Paul Sagan 617-852-0495 LaVoie Strategic Communications Group, Inc. biolife@lavoiegroup.com

100 Deals associated with Dulaglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Argentina	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Australia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Brazil	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Bulgaria	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Canada	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Chile	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Colombia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Czechia	Eli Lilly & Co.	22 Jul 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255433 (SURPASS-CVOT \| SURPASS, CTgov)	Phase 3	Diabetes Mellitus, Type 2	13,299	Dulaglutide	gstalfkqwk = hyfzhvhhmb bbwnbioeca (mibnkgrqrx, pxdlpuvmac - xxtbreqwzr) View more	-	08 Jul 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2 \| Mild cognitive disorder	1,320	GLP-1 RAs	ppjzdkttrw(yapiwiapxx): ARD = -4.9 (95.0% CI, -9.4 to -0.4) View more	Positive	20 Jun 2026
				DPP4i
NCT04255433 (Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2	13,165	Tirzepatide	vhmfatgrsx(bytqvmdzaf) = yznqhifyrn lymyebpves (kczzulphrv ) View more	Positive	01 Jun 2026
				Dulaglutide	vhmfatgrsx(bytqvmdzaf) = ickqtdwtpx lymyebpves (kczzulphrv ) View more
ASCO2026	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HR+/HER2-	1,208	GLP-1 RA+ET+CDK4/6i	-	Positive	29 May 2026
				ET+CDK4/6i alone	lhtigvbqcb(fbbnxevfvq) = csiiwumpmc nojgpqifjf (eexcvkilmg )
DDW2026	Not Applicable	Liver Cirrhosis	119,317	GLP-1 RAs (semaglutide, liraglutide, dulaglutide, tirzepatide)	afljvnvgeh(ekdusgxhwl): OR = 0.38 (95.0% CI, 0.36 - 0.41) View more	Positive	02 May 2026
				Non-GLP-1 RA users
DDW2026	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	400	GLP-1 RAs	gnwgrdayim(larplyfeme): OR = 0.22 (95.0% CI, 0.12 - 0.39) View more	Positive	02 May 2026
				Non-GLP-1 RAs
AAD2026	Not Applicable	Injection Site Reaction	15,780	Semaglutide	oapdkhvcla(dsrzlmzbsf) = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). ehekrtknsi (bhfussjrvg )	Positive	27 Mar 2026
				Liraglutide
NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	gsxgaadqut(jehyzxxtia) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation dgzntaazvi (albeuqqlfo )	-	10 Oct 2025
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	ihthnejqkr(ndxlqbpqlq) = dzeysfmjdl hsluqgbzwn (uuuymkcxtk ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	ihthnejqkr(ndxlqbpqlq) = zicyjsbtvb hsluqgbzwn (uuuymkcxtk ) View more
NCT04255433 (SURPASS-CVOT, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,299	Mounjaro (tirzepatide)	iwrwwqageg(llacomrazq): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more	Non-inferior	31 Jul 2025
				Trulicity (dulaglutide)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis